When my bone marrow transplant failed to treat my leukemia, I thought, “This is it.” Doctors reassured my parents that it was only a short-term issue, but weeks turned into a long and challenging journey.

Having just turned 13, I was overwhelmed by thoughts of missing out on growing up, having a family, and living a normal life.

Then, we heard about a groundbreaking trial at Great Ormond Street Hospital in London that felt straight out of science fiction. The doctors described how they would enhance my CAR T cells to fight and eliminate the cancer cells in my body.

Everything began after Easter in 2021. Upon returning to school after the COVID-19 lockdown, I struggled with fatigue. My energy levels plummeted, and I eventually developed pneumonia, leading to my hospitalization.

During a particularly concerning morning, my father took me to the A&E hospital. My condition worsened, and I found myself in intensive care, unaware that I was beginning chemotherapy for my leukemia—characterized by malignant immune cells.

Doctors faced challenges diagnosing my ailment, likely due to my rare T-cell leukemia. Following an ineffective month of chemotherapy, I underwent a bone marrow transplant in Sheffield, which aimed to replace cancerous stem cells with healthy ones.

Expecting to be home for Christmas, I instead faced unanticipated complications and returned to the hospital. It was a devastating realization that the transplant hadn’t worked.

With no further options available, my family was devastated. My mother described the immeasurable pain of losing hope.

In their search for alternatives, they learned about CAR T-cell therapy, which transforms T cells to effectively target cancer cells. However, they soon discovered its limited effectiveness in treating T-cell leukemia.

Then, my consultant introduced us to Professor Waseem Qasim, who was pioneering the use of CRISPR base editing to enhance CAR T cells for patients like me. This innovative treatment offered renewed hope.

Despite my parents’ reservations about the trial, they ultimately supported my decision, recognizing my desire to contribute positively, even if it didn’t benefit me directly.

Before the CAR T cell collection, I underwent rigorous pre-treatment for two weeks in the hospital. It was exciting to see the treatment take effect, and I felt a wave of relief when the doctors confirmed the cells were multiplying.

The staff at Great Ormond Street were exceptional. Even in isolation, I forged connections with other patients and staff, finding support in our shared struggles. Unfortunately, I lost a friend who didn’t survive the bone marrow transplant.

Four weeks later, I received the incredible news that my bone marrow was cancer-free. Follow-up tests continually confirmed the absence of detectable cancer cells, leading to a second transplant to reinforce my healing.

The hardest transition came after returning home. No longer surrounded by a supportive medical team, I faced strict isolation to prevent infection while trying to adjust to life outside the hospital.

Today, I am in remission but continue to manage the side effects of my treatment. While my thyroid is underactive due to chemotherapy, I am committed to ongoing treatment. I dream of a future where CAR T therapy could provide immediate relief without extensive chemotherapy.

Now 17 and pursuing my A-levels, I am excited about my future in biomedical science. My goal is to help others as much as I have been helped.

I actively participate in conferences to share my journey, and I had the honor to meet Professor David Liu, the innovator behind base editing. It was an emotional experience for me.

I cherish the opportunity to advocate for the importance of scientific research. Without the advancements borne from this work, I wouldn’t be here today.

As told to Michael Le Page